GlassScriptPhysician profile
Terry A Belden
NPI 1467428821
$6,230.78
in general payments reported to CMS, 2019-2025
45 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,156 · 2020: $753 · 2021: $1,080 · 2022: $787 · 2023: $751 · 2024: $969 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $892.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $528.31 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $399.16 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novartis Pharmaceuticals Corporation | $375.86 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $312.70 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.85 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $307.82 | 2019-2022 | |
| Amarin Pharma, INC. | $282.33 | 2019-2022 | |
| Pfizer INC. | $239.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $239.11 | 2019-2025 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $233.04 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $212.69 | 2019-2023 | Myrbetriq |
| Glaxosmithkline, LLC. | $193.12 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $165.86 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Alexion Pharmaceuticals, INC. | $142.28 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Belden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.